GSK Wins First Lung Cancer Approval With Jideytro, Days After Closing $10.6B Nuvalent Deal

The U.S. Food and Drug Administration has granted accelerated approval to Jideytro (zidesamtinib), a targeted therapy for a rare form of lung cancer, handing GSK its first approved lung cancer medicine just one week after the British drugmaker closed a $10.6 billion acquisition to acquire it.

The approval, announced July 22, 2026, covers adults with metastatic non-small cell lung cancer (NSCLC) whose tumors carry alterations in the ROS1 gene and who have already been treated with another therapy. It arrived nearly two months ahead of the FDA's September 18 decision deadline — a pace GSK attributes to the drug's breakthrough therapy and orphan drug designations.

A small patient group with few good options

ROS1 gene alterations drive only about 2% of non-small cell lung cancers. But because lung cancer is so common worldwide — roughly 50,000 people are diagnosed with ROS1-positive disease each year globally — even a narrow slice represents thousands of patients who currently cycle through a limited set of treatments.

Zidesamtinib was originally developed by Nuvalent, the biotech GSK acquired in a deal that ranks as its largest in eight years. According to the company, the drug is designed to work for longer, produce fewer side effects, and remain effective against resistance mutations that can blunt existing ROS1 inhibitors over time. Those are manufacturer claims tied to the drug's accelerated approval, which the FDA typically grants on early evidence while requiring follow-up trials to confirm long-term benefit.

Entering a competitive field

Jideytro joins a market already served by Pfizer's Xalkori and Roche's Rozlytrek, both approved for ROS1-positive lung cancer. GSK is betting that better durability and resistance coverage will help its new medicine stand out for patients whose cancer has progressed on those earlier options.

"The rapid progression of Jideytro from development to approval reflects both the strength of the underlying science and the urgent need for additional effective and tolerable treatments for ROS1-positive lung cancer," said Tony Wood, GSK's Chief Scientific Officer.

The Nuvalent purchase brought GSK more than a single product. The same transaction included neladalkib, another cancer drug currently under FDA review, signaling that the company's push into oncology — a years-long strategic priority — is likely to continue.

What this means for patients

For someone living with ROS1-positive lung cancer whose current treatment has stopped working, an additional approved option matters. A new drug in this class can offer another line of therapy when resistance develops — often the point at which choices run out.

Why ROS1 is a target at all

ROS1 is a receptor tyrosine kinase whose normal function in adults is not well understood — which is unusual for a cancer target and, in this case, useful.

The alterations that matter are gene fusions: a chromosomal rearrangement joins part of ROS1 to a different gene, producing a hybrid protein that is permanently switched on. The cell receives a continuous growth signal that no longer depends on any external instruction.

Tumours driven this way are frequently dependent on that single alteration for survival, a property described as oncogene addiction. Blocking the fused protein can therefore collapse the tumour rather than merely slow it — which is why response rates in fusion-driven lung cancers are typically far higher than in cancers driven by accumulated damage across many genes.

Because ROS1 does little in normal adult tissue, inhibiting it is also comparatively well tolerated.

What resistance looks like, and why it is the design goal

The company’s claim that the drug remains effective against resistance mutations addresses the predictable failure mode of this entire class.

Targeted therapies against fusion-driven cancers work well and rarely last. Under treatment pressure, tumour cells acquire further mutations in the target protein itself — typically altering the shape of the pocket the drug binds, so the drug no longer fits while the protein keeps signalling.

Certain positions recur across patients and across drugs, because only a few changes preserve the protein’s function while excluding the inhibitor. Designing a compound that still binds those altered shapes is what a next-generation inhibitor is for.

A second problem is the brain. ROS1-positive lung cancer spreads to the central nervous system in a substantial share of patients, and earlier drugs in this class penetrate the blood-brain barrier poorly — so disease can progress in the brain while remaining controlled everywhere else. Brain penetration is a standard requirement for later entrants in these fusion-driven lung cancers.

What accelerated approval leaves open

The pathway permits approval on a measure reasonably likely to predict benefit — usually tumour response rate — rather than on demonstrated survival gain.

That is a defensible trade in a small population where a randomised survival trial would take years to enrol and complete, and it means the evidence supporting approval is narrower than the label implies. Confirmatory trials are required, and drugs approved this way have been withdrawn when those failed.

In a rare, previously treated population it is also the only realistic route. Waiting for survival data would mean the patients who need the drug now do not get it.

That said, accelerated approval is not the final word. It allows a promising drug to reach patients sooner, but the FDA still expects confirmatory data down the line, and real-world results can differ from early trials. Anyone weighing a new therapy should discuss its risks, benefits, and evidence with their oncologist rather than relying on a drug's newness alone.